New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 3, 2014
05:34 EDTBAYRY, REGNBayer, Regeneron announce regulatory submission of Eylea in Japan
Regeneron Pharmaceuticals (REGN) announced that Bayer HealthCare's (BAYRY) Japanese subsidiary, Bayer Yakuhin, has submitted an application for marketing authorization for Eylea Injection for the treatment of patients with diabetic macular edema, or DME, to the Japanese Ministry of Health, Labour and Welfare.
News For BAYRY;REGN From The Last 14 Days
Check below for free stories on BAYRY;REGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
08:08 EDTREGNSanofi and Regeneron report positive Phase 2 results of alirocumab
Subscribe for More Information
05:57 EDTBAYRYBayer reports Q2 net income EU 953M vs. EU 841M last year
Subscribe for More Information
05:55 EDTBAYRYBayer says Stivargahas approved in Europe for GIST
Subscribe for More Information
July 29, 2014
18:38 EDTREGNRegeneron receives FDA approval for EYLEA for treatment of DME
Regeneron Pharmaceuticals announced that the FDA has approved EYLEA Injection for the treatment of Diabetic Macular Edema, or DME. The approval of EYLEA in DME was based on the one-year data from the phase 3 VISTA-DME and VIVID-DME studies of 862 patients. In Europe, the Committee for Medicinal Products for Human Use has given a positive opinion recommending approval for EYLEA in the treatment of DME. Regulatory submissions have also been made in Japan, Asia Pacific, and Latin America for the treatment of DME. In Japan, EYLEA has been additionally submitted for approval to regulators for the treatment of choroidal neovascularization secondary to pathologic myopia. A regulatory submission has been made in the U.S. and Europe for EYLEA for the treatment of Macular Edema following Branch Retinal Vein Occlusion.
July 25, 2014
07:32 EDTBAYRYAmerican Veterinary Medical Association to hold a conference
Subscribe for More Information
05:35 EDTBAYRYBayer, Onyx reports NEXAVAR Phase 3 trial did not meet primary endpoint
Subscribe for More Information
July 24, 2014
13:06 EDTBAYRYBayer treatment for systemic sclerosis receives FDA orphan designation
Subscribe for More Information
07:12 EDTBAYRYEvogene announces amendment to Bayer wheat agreement
Subscribe for More Information
July 21, 2014
10:02 EDTREGNOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Adeptus Health (ADPT) initiated with a Buy at Dougherty... Amphastar (AMPH) initiated with a Buy at Jefferies... Eclipse Resources (ECR) initiated with a Neutral at SunTrust... Fidelity National (FNF) initiated with a Buy at SunTrust... First American (FAF) initiated with a Buy at SunTrust... GoPro (GPRO) initiated with a Hold at Stifel... Imprivata (IMPR) initiated with an Outperform at Wells Fargo... Lifetime Brands (LCUT) initiated with a Buy at Sidoti... Materialise (MTLS) initiated with a Buy at BB&T... Regeneron (REGN) initiated with a Buy at Argus... STAG Industrial (STAG) initiated with a Buy at Sandler O'Neill... Signature Group (SGGH) initiated with a Buy at B. Riley... TCP International (TCPI) initiated with a Buy at Canaccord... Tessera (TSRA) initiated with a Buy at Craig-Hallum... Xunlei (XNET) initiated with a Perform at Oppenheimer.
07:42 EDTREGNRegeneron initiated with a Buy at Argus
Target $375.
07:14 EDTBAYRYAmerican Association of Physicists in Medicine to hold annual meeting
56th Annual Meeting of AAPM to be held in Austin, Texas on July 20-25.
July 18, 2014
06:10 EDTREGNRegeneron announces results from Phase 3 VIVID-DME trial of EYLEA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use